JP2004500320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500320A5 JP2004500320A5 JP2000593639A JP2000593639A JP2004500320A5 JP 2004500320 A5 JP2004500320 A5 JP 2004500320A5 JP 2000593639 A JP2000593639 A JP 2000593639A JP 2000593639 A JP2000593639 A JP 2000593639A JP 2004500320 A5 JP2004500320 A5 JP 2004500320A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tweak
- composition
- monoclonal antibody
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000026278 immune system disease Diseases 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 102000058177 human TNFSF12 Human genes 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000830601 Mus musculus Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11616899P | 1999-01-15 | 1999-01-15 | |
| US60/116,168 | 1999-01-15 | ||
| PCT/US2000/001044 WO2000042073A1 (en) | 1999-01-15 | 2000-01-14 | Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010188938A Division JP5592195B2 (ja) | 1999-01-15 | 2010-08-25 | Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004500320A JP2004500320A (ja) | 2004-01-08 |
| JP2004500320A5 true JP2004500320A5 (https=) | 2009-08-20 |
| JP5550799B2 JP5550799B2 (ja) | 2014-07-16 |
Family
ID=22365656
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000593639A Expired - Fee Related JP5550799B2 (ja) | 1999-01-15 | 2000-01-14 | Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
| JP2010188938A Expired - Lifetime JP5592195B2 (ja) | 1999-01-15 | 2010-08-25 | Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
| JP2013006243A Withdrawn JP2013075916A (ja) | 1999-01-15 | 2013-01-17 | Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010188938A Expired - Lifetime JP5592195B2 (ja) | 1999-01-15 | 2010-08-25 | Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
| JP2013006243A Withdrawn JP2013075916A (ja) | 1999-01-15 | 2013-01-17 | Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20020015703A1 (https=) |
| EP (1) | EP1141027A1 (https=) |
| JP (3) | JP5550799B2 (https=) |
| KR (1) | KR20010102978A (https=) |
| CN (1) | CN1387538A (https=) |
| AU (1) | AU2507700A (https=) |
| BR (1) | BR0007556A (https=) |
| CA (1) | CA2358684C (https=) |
| CZ (1) | CZ20012548A3 (https=) |
| EA (1) | EA004590B1 (https=) |
| EE (1) | EE200100372A (https=) |
| HK (1) | HK1038755A1 (https=) |
| HU (1) | HUP0105044A3 (https=) |
| IL (1) | IL144007A0 (https=) |
| IS (1) | IS5986A (https=) |
| MX (1) | MXPA01007163A (https=) |
| NO (1) | NO20013340L (https=) |
| NZ (1) | NZ529355A (https=) |
| SK (1) | SK10042001A3 (https=) |
| TR (1) | TR200102021T2 (https=) |
| WO (1) | WO2000042073A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| US7001992B2 (en) * | 1997-05-30 | 2006-02-21 | Human Genome Sciences, Inc. | Antibodies to secreted protein HEMCM42 |
| MXPA01007163A (es) * | 1999-01-15 | 2002-03-27 | Biogen Inc | Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos. |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| US7495086B2 (en) | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
| EP2298333A3 (en) | 1999-12-20 | 2012-05-02 | Immunex Corporation | Tweak receptor |
| AU5951901A (en) | 2000-05-08 | 2001-11-20 | Biogen Inc | Method for promoting neovascularization |
| US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| AU8901901A (en) * | 2000-09-14 | 2002-03-26 | Biogen Inc | Tweak receptor agonists as anti-angiogenic agents background |
| MX352180B (es) * | 2002-04-09 | 2017-11-13 | Biogen Ma Inc | El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak. |
| US20070010658A1 (en) | 2002-10-29 | 2007-01-11 | Holtet Thor L | Trimeric binding proteins for trimeric cytokines |
| DE602004006871T2 (de) | 2003-07-24 | 2008-02-07 | Amgen Inc., Thousand Oaks | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen |
| WO2005018571A2 (en) * | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| EP1566636A1 (en) * | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
| EP1811838A4 (en) * | 2004-11-08 | 2009-07-22 | Univ Maryland | TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH |
| US7939490B2 (en) | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| WO2006089095A2 (en) * | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
| US20090068102A1 (en) * | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
| EP1853312B1 (en) * | 2005-03-07 | 2014-12-10 | Genentech, Inc. | Methods and compositions for modulating tweak and fn14 activity |
| CA2607697C (en) * | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| MEP35408A (en) * | 2005-05-27 | 2011-02-10 | Biogen Idec Inc | Tweak binding antibodies |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| AU2013200995B2 (en) * | 2005-05-27 | 2016-08-04 | Biogen Ma Inc. | Tweak binding antibodies |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| AU2006284922B2 (en) | 2005-08-30 | 2012-01-19 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins |
| US20100284933A1 (en) * | 2006-10-16 | 2010-11-11 | Biogen Idec Ma Inc. | Biomarkers of Multiple Sclerosis |
| EP2545938A1 (en) | 2007-08-03 | 2013-01-16 | Abbott Biotherapeutics Corp. | Therapeutic use of anti-tweak receptor antibodies |
| NZ590667A (en) * | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| JP2011526792A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| US20130124426A1 (en) * | 2008-10-02 | 2013-05-16 | ecoATM, Inc. | Method And Apparatus For Recycling Electronic Devices |
| US8093006B2 (en) | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
| SG10201502330TA (en) | 2009-08-03 | 2015-05-28 | Univ Miami | Method for in vivo expansion of t regulatory cells |
| US9068004B2 (en) | 2010-02-04 | 2015-06-30 | University Of Louisville Research Foundation, Inc. | TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration |
| AU2011311673B2 (en) | 2010-10-05 | 2015-09-17 | F. Hoffmann-La Roche Ag | Antibodies against human TWEAK and uses thereof |
| AU2012225246B2 (en) | 2011-03-10 | 2016-01-21 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
| US9456755B2 (en) | 2011-04-29 | 2016-10-04 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
| WO2013150043A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| US20140193410A1 (en) | 2013-01-09 | 2014-07-10 | University Of Miami | Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein |
| US9238034B2 (en) | 2013-07-09 | 2016-01-19 | The Translational Genomics Research Institute | FN14 antagonists and therapeutic uses thereof |
| US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
| JP2017029001A (ja) * | 2013-12-19 | 2017-02-09 | 国立研究開発法人産業技術総合研究所 | プロテインｇの細胞膜外ドメインの新規な改変型タンパク質 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| WO2017131972A1 (en) * | 2016-01-25 | 2017-08-03 | Oxytec Llc | Soil and water remediation method and apparatus for treatment of recalcitrant halogenated substances |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US11661360B2 (en) | 2020-06-18 | 2023-05-30 | Wp&E Technologies And Solutions, Llc | System for removing per- and polyfluorinated alkyl substances from contaminated aqueous streams, via chemical aided filtration, and methods of use thereof |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5200313A (en) | 1983-08-05 | 1993-04-06 | Miles Inc. | Nucleic acid hybridization assay employing detectable anti-hybrid antibodies |
| US4921698A (en) | 1984-05-25 | 1990-05-01 | Asahi Kasei Kogyo Kabushiki Kaisha | Polypeptide having gamma-interferon activity lacking amino acids coded by exon 4 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5073492A (en) | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| AT396939B (de) | 1990-05-29 | 1993-12-27 | Alois Dipl Ing Dr Jungbauer | Komplexes virales antigen von hiv-1 bindendes rekombinantes protein |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| EP0679716A4 (en) | 1993-11-12 | 1999-06-09 | Kenichi Matsubara | GENE SIGNATURE. |
| US20030198640A1 (en) | 1994-11-07 | 2003-10-23 | Human Genome Sciences, Inc. | Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta |
| US6544761B2 (en) | 1994-12-13 | 2003-04-08 | Human Genome Sciences, Inc. | Human tissue inhibitor of metalloproteinase-4 |
| ES2281898T3 (es) | 1994-12-13 | 2007-10-01 | Human Genome Sciences, Inc. | Inhibidor tisular humano de metaloproteinasa-4. |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US7129061B1 (en) | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
| CZ297387B6 (cs) * | 1996-08-07 | 2006-11-15 | Biogen Idec Ma Inc. | Sekvence DNA kódující ligand príbuzný TNF, polypeptid a zpusob jeho prípravy, protilátka reaktivní s polypeptidem a farmaceutická kompozice |
| US5858991A (en) | 1997-01-29 | 1999-01-12 | Vanderbilt University | Facilitation of wound healing with CM101/GBS toxin |
| CA2280231A1 (en) | 1997-02-12 | 1998-08-13 | Abbott Laboratories | Member of the tnf family useful for treatment and diagnosis of disease |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU7549498A (en) | 1997-06-03 | 1998-12-21 | Protegene Inc. | Human proteins having transmembrane domains and dnas encoding these prot eins |
| WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| JP4303883B2 (ja) | 1997-09-18 | 2009-07-29 | ジェネンテック・インコーポレーテッド | ＤｃＲ３ポリペプチドというＴＮＦＲ相同体 |
| EP1021542B1 (en) * | 1997-10-10 | 2009-03-04 | Genentech, Inc. | Apo-3 ligand |
| US20020072089A1 (en) | 1999-11-23 | 2002-06-13 | Holtzman Douglas A. | Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
| US6046381A (en) | 1998-04-30 | 2000-04-04 | The Regents Of The University Of California | Apolipoprotein E transgenic mice and assay methods |
| WO1999059614A1 (en) | 1998-05-20 | 1999-11-25 | Yale University | Modulation of angiogenesis and wound healing |
| EP1080194A2 (en) | 1998-05-29 | 2001-03-07 | Incyte Pharmaceuticals, Inc. | Human transmembrane proteins |
| CA2345382A1 (en) | 1998-10-16 | 2000-04-27 | Immunex Corporation | Inhibitors of platelet activation and recruitment |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| ES2327785T3 (es) | 1998-12-22 | 2009-11-03 | Genentech, Inc. | Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas. |
| MXPA01007163A (es) | 1999-01-15 | 2002-03-27 | Biogen Inc | Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos. |
| US20020004041A1 (en) | 1999-02-19 | 2002-01-10 | Albert Matthew L. | Methods for abrogating a cellular immune response |
| PT1626058E (pt) | 1999-03-08 | 2008-02-15 | Genentech Inc | Composições e métodos para o diagnóstico de tumores |
| US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| KR100510795B1 (en) | 1999-08-31 | 2005-08-30 | Compositions and Methods for the Treatment of Tumor | |
| EP2298333A3 (en) | 1999-12-20 | 2012-05-02 | Immunex Corporation | Tweak receptor |
| US7495086B2 (en) * | 1999-12-20 | 2009-02-24 | Immunex Corporation | TWEAK receptor |
| US6727225B2 (en) * | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| IL150571A0 (en) | 2000-01-03 | 2003-02-12 | Tr Associates L L C | Novel chimeric proteins and methods for using the same |
| US7927602B2 (en) | 2002-07-23 | 2011-04-19 | University Of Louisville Research Foundation, Inc. | Fas ligand-avidin/streptavidin fusion proteins |
| NZ521437A (en) | 2000-02-25 | 2004-04-30 | Immunex Corp | Integrin antagonists suitable as inhibitors of angiogenesis |
| AU5951901A (en) | 2000-05-08 | 2001-11-20 | Biogen Inc | Method for promoting neovascularization |
| US20040047854A1 (en) | 2001-07-27 | 2004-03-11 | Black Roy A. | Human disintegrin protein |
| US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| AU8901901A (en) | 2000-09-14 | 2002-03-26 | Biogen Inc | Tweak receptor agonists as anti-angiogenic agents background |
| JP4344519B2 (ja) | 2000-12-28 | 2009-10-14 | 旭化成ファーマ株式会社 | ＮＦ−κＢ活性化遺伝子 |
| EP1379264A4 (en) | 2001-03-21 | 2009-07-08 | Human Genome Sciences Inc | HUMAN SECRETED PROTEINS |
| US20040203083A1 (en) | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
| US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
| US6756101B2 (en) | 2001-07-16 | 2004-06-29 | Specialty Tapes, Division Of Rsw | Tape for use with high-speed webs and method of use thereof |
| WO2003040307A2 (en) | 2001-07-27 | 2003-05-15 | Human Genome Sciences, Inc. | Heteromultimeric tnf ligand family members |
| US20040091473A1 (en) | 2001-07-27 | 2004-05-13 | Dubose Robert F. | Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| US20030148314A1 (en) | 2001-08-01 | 2003-08-07 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer |
| US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
| MX352180B (es) * | 2002-04-09 | 2017-11-13 | Biogen Ma Inc | El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak. |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| WO2004074506A2 (en) | 2003-02-13 | 2004-09-02 | Mergen Ltd | Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers |
| WO2004079014A2 (en) | 2003-03-04 | 2004-09-16 | Arcturus Bioscience, Inc. | Signatures of er status in breast cancer |
| DE602004006871T2 (de) * | 2003-07-24 | 2008-02-07 | Amgen Inc., Thousand Oaks | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen |
| EP1566636A1 (en) | 2004-02-23 | 2005-08-24 | AXARON Bioscience AG | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
| EP1811838A4 (en) | 2004-11-08 | 2009-07-22 | Univ Maryland | TWEAK AS A THERAPEUTIC TARGET FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM IN CONNECTION WITH CEREBRAL OEDEM AND CELL DEATH |
| US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| US20090068102A1 (en) * | 2005-02-17 | 2009-03-12 | Biogen Idec Ma Inc. | Treating stroke |
| WO2006089095A2 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
| EP1853312B1 (en) | 2005-03-07 | 2014-12-10 | Genentech, Inc. | Methods and compositions for modulating tweak and fn14 activity |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| MEP35408A (en) | 2005-05-27 | 2011-02-10 | Biogen Idec Inc | Tweak binding antibodies |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| WO2006138219A2 (en) * | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| US20100284933A1 (en) * | 2006-10-16 | 2010-11-11 | Biogen Idec Ma Inc. | Biomarkers of Multiple Sclerosis |
| MX2010012324A (es) * | 2008-05-15 | 2011-01-14 | Biogen Idec Inc | Anticuerpos anti-fn14 y usos de los mismos. |
| WO2010085648A2 (en) | 2009-01-23 | 2010-07-29 | Linda Burkly C | Methods for reducing radiation-induced tissue damage |
| MX2011007936A (es) | 2009-01-30 | 2011-08-17 | Biogen Idec Inc | Metodos para regeneracion de tejido pancreatico. |
| AU2011311673B2 (en) * | 2010-10-05 | 2015-09-17 | F. Hoffmann-La Roche Ag | Antibodies against human TWEAK and uses thereof |
-
2000
- 2000-01-14 MX MXPA01007163A patent/MXPA01007163A/es unknown
- 2000-01-14 EA EA200100780A patent/EA004590B1/ru not_active IP Right Cessation
- 2000-01-14 IL IL14400700A patent/IL144007A0/xx unknown
- 2000-01-14 EP EP00903307A patent/EP1141027A1/en not_active Withdrawn
- 2000-01-14 NZ NZ529355A patent/NZ529355A/en not_active IP Right Cessation
- 2000-01-14 WO PCT/US2000/001044 patent/WO2000042073A1/en not_active Ceased
- 2000-01-14 CZ CZ20012548A patent/CZ20012548A3/cs unknown
- 2000-01-14 CA CA2358684A patent/CA2358684C/en not_active Expired - Lifetime
- 2000-01-14 CN CN00804735A patent/CN1387538A/zh active Pending
- 2000-01-14 HU HU0105044A patent/HUP0105044A3/hu unknown
- 2000-01-14 AU AU25077/00A patent/AU2507700A/en not_active Abandoned
- 2000-01-14 SK SK1004-2001A patent/SK10042001A3/sk unknown
- 2000-01-14 HK HK02100180.8A patent/HK1038755A1/zh unknown
- 2000-01-14 JP JP2000593639A patent/JP5550799B2/ja not_active Expired - Fee Related
- 2000-01-14 TR TR2001/02021T patent/TR200102021T2/xx unknown
- 2000-01-14 EE EEP200100372A patent/EE200100372A/xx unknown
- 2000-01-14 KR KR1020017008956A patent/KR20010102978A/ko not_active Withdrawn
- 2000-01-14 BR BR0007556-6A patent/BR0007556A/pt not_active Application Discontinuation
-
2001
- 2001-06-29 IS IS5986A patent/IS5986A/is unknown
- 2001-07-05 NO NO20013340A patent/NO20013340L/no not_active Application Discontinuation
- 2001-07-13 US US09/905,810 patent/US20020015703A1/en not_active Abandoned
-
2004
- 2004-08-11 US US10/916,141 patent/US7169387B2/en not_active Expired - Lifetime
-
2006
- 2006-10-04 US US11/542,745 patent/US7579001B2/en not_active Expired - Fee Related
-
2009
- 2009-07-20 US US12/506,006 patent/US20100061985A1/en not_active Abandoned
-
2010
- 2010-08-25 JP JP2010188938A patent/JP5592195B2/ja not_active Expired - Lifetime
-
2011
- 2011-06-30 US US13/173,604 patent/US8440189B2/en not_active Expired - Fee Related
-
2013
- 2013-01-17 JP JP2013006243A patent/JP2013075916A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004500320A5 (https=) | ||
| US7579001B2 (en) | Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders | |
| CN103221427B (zh) | 抗ox40抗体和使用其的方法 | |
| CN100374466C (zh) | 人il-12抗体 | |
| CN103946238B (zh) | 抗ox40抗体及使用其的方法 | |
| JP5693127B2 (ja) | Ｎｋｇ２ｄの調節 | |
| KR100574591B1 (ko) | 사람 ｇｐ39에 대한 사람화된 항체, 이러한 항체를함유하는 조성물 및 이의 치료학적 용도 | |
| JP2006507844A5 (https=) | ||
| JP2002501085A5 (https=) | ||
| CA2657763A1 (en) | Anti-il-6 monoclonal antibodies and uses thereof | |
| RU2012151478A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| KR20010005602A (ko) | 아이엘-6 안타고니스트를 유효성분으로 함유하는 감작 티 세포 관여 질환의 예방 또는 치료제 | |
| JP2010501164A5 (https=) | ||
| JP2009540018A (ja) | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 | |
| RU2007103826A (ru) | Иммуноглобулины | |
| JP2021501566A5 (https=) | ||
| EP2040730A2 (en) | Modulation of nkg2d | |
| Malviya et al. | Biological therapies for rheumatoid arthritis: progress to date | |
| CN110305215A (zh) | 新型抗lag-3抗体多肽 | |
| JP2021518166A (ja) | 新規抗ｌａｇ−３抗体ポリペプチド | |
| JP2013519690A5 (https=) | ||
| US20060172346A1 (en) | Methods of designing and producing novel compounds having improved binding affinity for CD154 or other trimeric proteins | |
| AU2001275224B2 (en) | Non-agonistic antibodies to human GP39, compositions containing, and therapeutic use thereof | |
| Andreakos | Monoclonal antibodies for immunological disorders: a review of recent patents | |
| MXPA99003283A (en) | Methods and compositions for immunomodulation |